Clinical trials: Relapsed/ Refractory Multiple Myeloma
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
This phase Ib trial tests the safety, side effects, and best dose of CC-92480 in combination with elotuzumab and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed)…
- Trial name
- NCT05981209
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abdullah Khan
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsed or Refractory Multiple Myeloma
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
- Trial name
- NCT05918250
- Testing
- mRNA-2736
- Where
- 13 sites in United States, Canada
- Sponsor
- ModernaTX, Inc.
Multiple Myeloma
Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate efficacy and safety of the combination regimen of bortezomib-bendamustine-dexamethasone in patients with relapsed or refractory multiple myeloma
- Trial name
- BBD (NCT01168804)
- Testing
- bendamustine plus bortezomib plus dexamethasone
- Where
- 8 sites in Austria, Czechia
- Volunteers
- 79 people
- Sponsor
- Austrian Forum Against Cancer
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, pomalidomide, and dexamethasone and to establish the recommended Phase 2 dose for combination treatment to…
- Trial name
- NCT07150104
- Testing
- Belantamab mafodotin, Nirogacestat, Pomalidomide
- Where
- 10 sites in Brazil, Canada and 6 more
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG2575 monotherapy or in combination with lenalidomide (R) and dexamethasone (d) in patients with…
- Trial name
- NCT04674514
- Testing
- APG-2575, Rd
- Where
- 12 sites in China
- Volunteers
- 48 people
- Sponsor
- Ascentage Pharma Group Inc.
Multiple Myeloma
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma
This research study is a Phase I/II clinical trial. It is done to determine the best doses that the investigational drug (P276-00) can be used safely.
- Trial name
- NCT00547404
- Testing
- P276-00
- Volunteers
- 35 people
- Sponsor
- Piramal Enterprises Limited
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
This phase II trial studies the side effects and the best dose of alemtuzumab when given together with fludarabine phosphate and low-dose total body irradiation (TBI) and how well it works before donor stem cell transplant in…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00040846
- Testing
- alemtuzumab, fludarabine phosphate, total-body irradiation
- Where
- 7 sites in United States, Italy
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.
- Trial name
- NCT00096837
- Testing
- Motexafin Gadolinium Injection
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
Multiple Myeloma, Plasma Cell Neoplasm
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM.
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm, Malignant Plasma Cell Neoplasm
- Trial name
- NCT05336383
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory
A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)
Purpose/Specific Aims The study will determine if there is a reduction in malignant cell burden when patients with relapsed and/or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) consume tea made from the dried…
- Trial name
- Soursop (NCT07771803)
- Testing
- Soursop tea
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roger Strair
Multiple Myeloma
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability of fluphenazine in patients with advanced multiple myeloma. The study will also describe the efficacy of this drug.
- Trial name
- NCT00821301
- Testing
- Fluphenazine HCl
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Immune Control
Relapsed and Refractory Multiple Myeloma
Efficacy Study of CYT997 in Multiple Myeloma
This is a clinical research study that is designed to test the safety of CYT997 when given to patients with multiple myeloma and to test if CYT997 has any activity against that cancer.
- Trial name
- NCT00664378
- Testing
- CYT997
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- Gilead Sciences
Multiple Myeloma
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT053 CAR-BCMA T in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT03975907
- Testing
- CAR-BCMA T Cells
- Where
- 23 sites in China
- Volunteers
- 121 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
This phase I/II trial studies the best dose and effect of belantamab mafodotin given together with lenalidomide and daratumumab in treating patients with multiple myeloma that has come back (relapsed), does not respond to…
- Conditions
- Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT04892264
- Testing
- Belantamab Mafodotin, Daratumumab, Dexamethasone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Leukemia, Lymphoma
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Monoclonal antibodies such as daclizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006350
- Testing
- daclizumab, therapeutic allogeneic lymphocytes, mycophenolate mofetil
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Multiple Myeloma
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT05164250
- Testing
- REGN5458
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
The purpose of the Phase 1 part of the study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of oprozomib in combination with pomalidomide and dexamethasone in adults with primary…
- Trial name
- NCT01999335
- Testing
- Oprozomib, Pomalidomide, Dexamethasone
- Where
- 17 sites in United States
- Volunteers
- 33 people
- Sponsor
- Amgen
Multiple Myeloma, Plasma Cell Leukemia
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
This is a 2-phase study during which patients with relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL), who have already received at least two previous treatments, will receive investigational study drug…
- Trial name
- NCT00821249
- Testing
- ARRY-520, KSP(Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous, Dexamethasone, steroid; oral
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.